Effect of reducing dietary salt intake on the way blood vessels work

Not Applicable

• Conditions: Metabolic syndrome; Endothelial function; Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system; Metabolic and Endocrine - Metabolic disorders

• Registration Number: ACTRN12609000321246
• Lead Sponsor: CSIRO Human Nutrition

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-05-21
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Weight stable individuals with systolic blood pressure between 120-139mmHg and diastolic blood pressure between 80-89mmHg. Those with and without the metabolic syndrome (defined as waist circumference >94cm for men and >80cm for women plus two of the following: fasting triglycerides (TG) = to or > 1.7mmol/L, high density lipoprotein (HDL) cholesterol<1.03 (men) or 1.29 (women), fasting glucose 5.6-6.9mmol/L) will be eligible to participate in the study.

Exclusion Criteria

Previous cardiovascular disease, treated hypertension, significant weight loss (>5% body weight) in the previous 6months, use of non-steroidal anti-inflammatory drugs, known metabolic disease such as liver or kidney disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in endothelial function as measured by flow-mediated dilatation (FMD)[FMD is measured at each of the following time points: Baseline (start of the intervention), 2 days after baseline, week6, 2 days after week 6 and at week 12]